Core Insights - In the first half of 2025, China achieved significant results in innovative medical devices, with 43 innovative drugs and 45 innovative medical devices approved, representing year-on-year growth of 59% and 87% respectively, marking a historical high for medical device approvals in the same period [1] - The industry faces a "three high" dilemma: high R&D investment, high equipment costs, and high market conversion cycles, which traditional credit models struggle to address due to the "light asset, heavy technology" nature of biopharmaceutical companies [1] - The implementation of the "Several Provisions on the Financing Lease Management of Medical Devices in Pudong New Area" introduces 12 innovative clauses, establishing a full-cycle service loop of "equipment financing - clinical verification - market promotion," which is expected to reshape the industry-finance ecosystem [1] Event Overview - The Financing Lease Industry Forum will be held on August 15, co-hosted by Yicai Media, Shanghai Financing Lease Industry Association, and Shanghai Trading Group, focusing on exploring a dual-driven model of "financial tools + industrial policies" to inject new momentum into the development of biopharmaceutical companies [1][4] Agenda Highlights - Keynote speeches will cover the development trends and financing needs of the biopharmaceutical (device) industry, innovative leasing business practices, and interpretations of the new financing lease regulations [5][6]